A new way to identify possible therapeutic targets for patients with drug resistant melanoma has been developed by researchers. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.